Cemiplimab before surgery for early-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving the drug cemiplimab before surgery can help treat early-stage non-small cell lung cancer. The goal is to see if it shrinks the tumor or improves outcomes when followed by standard surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer (NSCLC) that is stage I or II (tumor size 2–3.9 cm) and has not spread to lymph nodes.
- Your tumor must show high activity on a PET scan (SUVmax >6.2) or be moderately/poorly differentiated on biopsy.
- You must be healthy enough for lung surgery, with lung function tests showing predicted post-surgery FEV1 and DLCO above 40%.
- You must have an ECOG performance status of 0 or 1 (meaning you are fully active or only restricted in physically strenuous activity).
- You must not have certain genetic mutations (EGFR or ALK) in your tumor.
- You must not have an active autoimmune disease, uncontrolled heart disease, or certain infections (like HIV, hepatitis, or tuberculosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two drugs, cemiplimab and dupilumab, given before surgery for early-stage non-small cell lung cancer. The goal is to see if these drugs can shrink the tumor and improve outcomes.
This study tests two drugs, dupilumab and cemiplimab, given before surgery for early-stage lung cancer. The goal is to see if these immune-boosting medicines can shrink the tumor and improve outcomes.
This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.
This trial tests giving just three cycles of immunotherapy (cemiplimab) without surgery or radiation, specifically for people with early-stage (stage IA) non-small cell lung cancer who cannot have surgery. It aims to see if this shorter treatment can control the cancer with fewer side effects.
This observational study looks at how well cemiplimab works and how safe it is for adults with advanced non-small cell lung cancer in everyday care in Europe. It mainly follows patients already prescribed cemiplimab, and asks them to complete questionnaires.
This trial tests a drug called cemiplimab, which helps your immune system fight cancer. It is given before and after surgery to try to reduce the chance of the cancer coming back.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.